Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study - Candlesense
ASC Clinical trials

Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study

- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. - Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron. -...

Related Questions

Could this differentiated PK profile lead to regulatory or partnership advantages compared to competitors, and what risks remain? How will the reported 2.3‑3.3× higher exposure vs. orforglipron affect ASC's valuation and expected market share in the GLP‑1 agonist space? What are the anticipated timelines and success criteria for subsequent Phase II/III trials based on the Phase Ib data?
Find similar articles on Candlesense prnewswire